Skip to main content
Home

Main navigation

  • Company
    • Company profile
    • Leadership team
    • Board of Directors
  • R&D Programs
    • Pipeline overview
    • Rupitasertib
    • EVX-020
  • Partnering
  • Careers
  • Contact
  • Search
  1. Home
  2. Media

All press releases

  • Evexta Bio Appoints Edith A. Perez as Scientific Advisor

    October 25, 2024
  • Evexta Bio appoints Robert Doebele as CMO consultant

    July 29, 2024
  • Evexta Bio appoints Shawn M. Leland as Chairman of the Board of Directors

    June 19, 2024
  • Evexta Bio Reports Progress towards Clinical Development of Rupitasertib in Advanced Breast Cancer

    April 22, 2024
  • Evexta Bio Announces the Appointment of Paul Gineste, PharmD, as Chief Development Officer

    January 4, 2024
  • Evexta Bio Announces the Appointment of Paul Gineste, PharmD, as Chief Development Officer

    January 4, 2024
  • Diaccurate Announces the Appointment of Scott Filosi as CEO and Corporate Name Change to Evexta Bio

    November 6, 2023
  • Diaccurate Announces Updated Data on its Novel PAM Pathway Inhibitor DIACC3010 in Patients with ER+ HER2- Metastatic Breast Cancer to be Presented at AACR 2023

    April 6, 2023
  • Diaccurate receives support from Bpifrance to conduct its DIACC2020 Program on the development of new payloads for antibody-drug conjugates (ADCs)

    January 5, 2023
  • Diaccurate appoints Laurence Riot Lamotte as Chief Financial Officer

    February 8, 2022

Pagination

  • 1
  • 2
  • ›› Next page
  • Last » Last page

Location

Headquarters: 104 Bd de Sébastopol, 75003 Paris

  33 (0)1 78 96 41 70

Stay in touch

Subscribe to our newsletter

Contact us

Follow us

  

Footer

  • Legal info
  • Privacy Notice
  • Cookies Notice